Regeneron Pharmaceuticals Inc (MIL:1REGN)
€ 757 -25.2 (-3.22%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 79/100

Regeneron Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 05:15PM GMT
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay. Welcome to the afternoon sessions of the BofA Virtual Vegas Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here, and I have Alec Stranahan from my team on the line as well.

And we're thrilled to have Regeneron for a session today. And with us today, we have CFO, Bob Landry; and Head of Commercial, Marion McCourt. Bob, Marion, welcome. We also have Justin Holko from the IR.

Hey, guys.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Hey, Geoff. Thanks. Good afternoon, everyone. Thanks for joining us today. And Geoff and Alec, thanks for inviting us to your conference. We always look forward to attend the annual conference. This year's virtual, but I'm sure we'll be in person next year. Happy to be there.

So before we begin, let me remind everyone that remarks made in the webcast include forward-looking statements about Regeneron. Each forward-looking statement is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot